|Articles|January 1, 2006

Experts weigh benefits, risks of Allergan-Inamed merger

National report — A proposed $3.2 billion merger of Botox-maker Allergan and breast-implant maker Inamed would ultimately benefit dermatologists, an Allergan official says.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME